Karatrasoglou E, Dimou M, Piperidou A, Lakiotaki E, Korkolopoulou P, Vassilakopoulos T
Int J Mol Sci. 2023; 24(18).
PMID: 37762410
PMC: 10531792.
DOI: 10.3390/ijms241814110.
Zhang H
Int J Hematol. 2018; 107(5):502-512.
PMID: 29380180
DOI: 10.1007/s12185-018-2414-6.
Lee J, Vo T, Fruman D
Br J Clin Pharmacol. 2016; 82(5):1213-1228.
PMID: 26805380
PMC: 5061788.
DOI: 10.1111/bcp.12888.
Wang X, Chu Y, Wang W, Yuan W
Int J Hematol. 2016; 103(5):510-8.
PMID: 26791377
DOI: 10.1007/s12185-016-1944-z.
Xie R, He W, Shen M, Shou X, Wang Y, Bao W
J Neurooncol. 2015; 125(1):79-89.
PMID: 26297046
DOI: 10.1007/s11060-015-1895-x.
Mantle cell lymphoma: taking therapeutic advantage of new insights into the biology.
Tang T, Martin P
Curr Hematol Malig Rep. 2014; 9(3):254-61.
PMID: 25023397
DOI: 10.1007/s11899-014-0221-6.
Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies.
Chao M
Cancer Manag Res. 2013; 5:251-69.
PMID: 24049458
PMC: 3775637.
DOI: 10.2147/CMAR.S34273.
A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas.
Kim S, Kang H, Kim J, Eom H, Huh J, Ko Y
Invest New Drugs. 2013; 31(6):1514-21.
PMID: 23975510
DOI: 10.1007/s10637-013-0015-z.
Association of AMP-activated protein kinase with risk and progression of non-Hodgkin lymphoma.
Hoffman A, Demanelis K, Fu A, Zheng T, Zhu Y
Cancer Epidemiol Biomarkers Prev. 2013; 22(4):736-44.
PMID: 23396962
PMC: 3631103.
DOI: 10.1158/1055-9965.EPI-12-1014.
A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma.
Renner C, Zinzani P, Gressin R, Klingbiel D, Dietrich P, Hitz F
Haematologica. 2012; 97(7):1085-91.
PMID: 22315486
PMC: 3396682.
DOI: 10.3324/haematol.2011.053173.
The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas.
Argyriou P, Economopoulou P, Papageorgiou S
Adv Hematol. 2011; 2012:435342.
PMID: 21822434
PMC: 3124126.
DOI: 10.1155/2012/435342.
Utility of mTOR inhibition in hematologic malignancies.
Younes A, Samad N
Oncologist. 2011; 16(6):730-41.
PMID: 21632450
PMC: 3228224.
DOI: 10.1634/theoncologist.2010-0318.
Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma.
Galimberti S, Petrini M
Cancer Manag Res. 2010; 2:181-9.
PMID: 21188109
PMC: 3004564.
DOI: 10.2147/cmar.s7960.
Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma.
Samad N, Younes A
Onco Targets Ther. 2010; 3:167-78.
PMID: 20856791
PMC: 2939769.
DOI: 10.2147/ott.s8147.
8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle cell lymphoma.
Dennison J, Shanmugam M, Ayres M, Qian J, Krett N, Medeiros L
Blood. 2010; 116(25):5622-30.
PMID: 20844237
PMC: 3031409.
DOI: 10.1182/blood-2010-05-285866.
Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line.
Chen R, Chubb S, Cheng T, Hawtin R, Gandhi V, Plunkett W
Cancer Res. 2010; 70(16):6587-97.
PMID: 20663900
PMC: 2929954.
DOI: 10.1158/0008-5472.CAN-09-3578.
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors.
Janne P, Gray N, Settleman J
Nat Rev Drug Discov. 2009; 8(9):709-23.
PMID: 19629074
DOI: 10.1038/nrd2871.
Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies.
Teachey D, Grupp S, Brown V
Br J Haematol. 2009; 145(5):569-80.
PMID: 19344392
PMC: 2784662.
DOI: 10.1111/j.1365-2141.2009.07657.x.
Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma.
Jones R, Chen Q, Voorhees P, Young K, Bruey-Sedano N, Yang D
Clin Cancer Res. 2008; 14(17):5416-25.
PMID: 18765533
PMC: 2576518.
DOI: 10.1158/1078-0432.CCR-08-0150.
Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
Alyea E, Li S, Kim H, Cutler C, Ho V, Soiffer R
Biol Blood Marrow Transplant. 2008; 14(8):920-6.
PMID: 18640576
PMC: 3805273.
DOI: 10.1016/j.bbmt.2008.05.024.